Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet (PETEChIA)

Poitiers University Hospital

Status and phase: Completed; Phase 3

Conditions: Treatment by Antiplatelet; Minor Traumatic Brain Injury

Treatments: Biological: S100B protein dosing

Study type: Interventional

Funder types: Other

Identifiers

NCT03780062

PETEChIA

Details and patient eligibility

About

All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.

No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.

Enrollment: 720 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 Years old
• Minor traumatic brain injury measured by a Glasgow score between 13 and 15
• Antiplatelet agent therapy
• Free subject without tutorship or curatorship

Exclusion criteria

• Age < 18 years old
• Glasgow score <13
• Traumatic brain injury older than 6 hours
• Patient without any social security system
• Patient with renforced protection (tutorship, curatorship, …)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

720 participants in 1 patient group

S100B protein dosing

Experimental group

Treatment:

Biological: S100B protein dosing